Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA4 | P22459 | 1/20 | 0.39 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.39 |
| ▸ | KCNAB1 | Q14722 | 1/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7996386 | 0.82 | — | — | |
| SCHEMBL42141 | 0.80 | FFAR3 (0.52) | KCNA4KCNA1KCNAB1FFAR3 | |
| SCHEMBL7258460 | 0.80 | KCNA4 (0.43) | KCNA4KCNA1KCNAB1FFAR3 | |
| SCHEMBL16153587 | 0.78 | KCNA4 (0.37) | KCNA4KCNA1KCNAB1FFAR3 | |
| SCHEMBL9339249 | 0.78 | FFAR3 (0.32) | FFAR3 | |
| SCHEMBL1871799 | 0.78 | PKM (0.37) | KCNA4KCNA1KCNAB1FFAR3 | |
| Hydrochloric Acid SCHEMBL15522635 | 0.78 | FFAR3 (0.50) | KCNA4KCNA1KCNAB1FFAR3 | |
| SCHEMBL7258643 | 0.78 | KCNA4 (0.37) | KCNA4KCNA1KCNAB1FFAR3 | |
| SCHEMBL7733528 | 0.78 | KCNA4 (0.37) | KCNA4KCNA1KCNAB1FFAR3 | |
| SCHEMBL21040847 | 0.74 | ALDH1A1 (0.35) | KCNA4KCNA1KCNAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190248793-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2019-08-15 | — | — | US | disclosed |
| US-20180105529-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-04-19 | — | — | US | disclosed |
| WO-2017218219-A1 | NOVEL DERIVATIVES OF CURCUMINOIDS AND USE THEREOF AS AN ANTICANCER AGENT | CHINA MEDICAL UNIVERSITY (TW) | 2017-12-21 | — | — | WO | disclosed |
| EP-2393798-B1 | TUNED SYNTHETIC DENDRIMER CALIBRANTS FOR MASS SPECTROMETRY | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016201310-A1 | HYBRID NANOPARTICLES CONTAINING DENDRONS, METHODS OF PRODUCING SUCH HYBRID NANOPARTICLES, AND USES THEREOF | RHODIA OPERATIONS (FR) | 2016-12-15 | — | — | WO | disclosed |
| WO-2016174079-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-11-03 | — | — | WO | disclosed |
| US-9051336-B2 | Regioselective acylation of rapamycin at the C-42 position | SANDOZ (CH) | 2015-06-09 | — | — | US | disclosed |
| US-20150132854-A1 | Tuned Synthetic Dendrimer Calibrants for Mass Spectrometry | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2015-05-14 | — | — | US | disclosed |
| US-8846848-B2 | Tuned synthetic dendrimer calibrants for mass spectrometry | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140081016-A1 | REGIOSELECTIVE ACYLATION OF RAPAMYCIN AT THE C-42 POSITION | SANDOZ AG (CH) | 2014-03-20 | — | — | US | disclosed |
| US-20110183939-A1 | NOVEL PYROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2011-07-28 | — | — | US | disclosed |
| US-20110183939-A1 | NOVEL PYROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2011-07-28 | — | — | US | disclosed |
| EP-2336109-A1 | NOVEL PYRROLINONE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING SAME | Shionogi&Co., Ltd. (JP) | 2011-06-22 | — | — | EP | disclosed |
| EP-2336109-A1 | NOVEL PYRROLINONE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING SAME | Shionogi&Co., Ltd. (JP) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010091109-A2 | TUNED SYNTHETIC DENDRIMER CALIBRANTS FOR MASS SPECTROMETRY | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010035727-A1 | NOVEL PYRROLINONE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING SAME | 塩野義製薬株式会社 (JP) | 2010-04-01 | — | — | WO | disclosed |
| US-6458521-B1 | OPTICALLY RECORDED SOUND TRACKS IN COLOR MOTION PICTURE FILMS | EASTMAN KODAK COMPANY | 2002-10-01 | — | — | US | disclosed |
| EP-0498381-B1 | Novel yellow couplers for photographic elements and processes | EASTMAN KODAK CO (US) | 1994-06-15 | — | — | EP | disclosed |
| EP-0498381-A1 | Novel yellow couplers for photographic elements and processes | EASTMAN KODAK COMPANY (US) | 1992-08-12 | — | — | EP | disclosed |
| US-5118599-A | A 1,3-dioxane-5-carbonyl acetanilide, can be used a 4-equivalent couplers | EASTMAN KODAK COMPANY | 1992-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183939-A1 | NOVEL PYROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | P2RX3, P2RX7, P2RX2 | KCNA4 82/4885KCNA1 36/4885KCNAB1 93/4885 |
| US-20180105529-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | ZC3HAV1, MAVS, TYMP | KCNA4 3744/4885KCNA1 4149/4885KCNAB1 4366/4885 |
| US-20140081016-A1 | REGIOSELECTIVE ACYLATION OF RAPAMYCIN AT THE C-42 POSITION | RICTOR, RPTOR, MTOR | KCNA4 2056/4885KCNA1 1999/4885KCNAB1 1615/4885 |
| US-20190248793-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | ZC3HAV1, MAVS, TYMP | KCNA4 3744/4885KCNA1 4149/4885KCNAB1 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.